KR20060002708A - 자궁내막증 및 부인과질환의 치료약 - Google Patents
자궁내막증 및 부인과질환의 치료약 Download PDFInfo
- Publication number
- KR20060002708A KR20060002708A KR1020047016387A KR20047016387A KR20060002708A KR 20060002708 A KR20060002708 A KR 20060002708A KR 1020047016387 A KR1020047016387 A KR 1020047016387A KR 20047016387 A KR20047016387 A KR 20047016387A KR 20060002708 A KR20060002708 A KR 20060002708A
- Authority
- KR
- South Korea
- Prior art keywords
- lactic acid
- polyl
- endometriosis
- points
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 49
- 201000010099 disease Diseases 0.000 title claims abstract description 48
- 239000003814 drug Substances 0.000 title claims abstract description 30
- 229940079593 drug Drugs 0.000 title claims abstract description 24
- 201000009273 Endometriosis Diseases 0.000 title claims description 38
- 229940126585 therapeutic drug Drugs 0.000 claims abstract description 40
- 239000004310 lactic acid Substances 0.000 claims abstract description 37
- 239000000203 mixture Substances 0.000 claims abstract description 23
- 125000004122 cyclic group Chemical group 0.000 claims abstract description 21
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 claims abstract description 16
- 239000004480 active ingredient Substances 0.000 claims abstract description 14
- 230000002829 reductive effect Effects 0.000 claims abstract description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229910001873 dinitrogen Inorganic materials 0.000 claims abstract description 7
- 238000009833 condensation Methods 0.000 claims description 12
- 230000005494 condensation Effects 0.000 claims description 12
- 230000000694 effects Effects 0.000 abstract description 34
- 238000010438 heat treatment Methods 0.000 abstract description 6
- 208000024891 symptom Diseases 0.000 description 35
- 208000005171 Dysmenorrhea Diseases 0.000 description 11
- 208000002193 Pain Diseases 0.000 description 11
- 230000036407 pain Effects 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- 238000012360 testing method Methods 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 230000036039 immunity Effects 0.000 description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- 210000005168 endometrial cell Anatomy 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 210000004291 uterus Anatomy 0.000 description 5
- 206010013935 Dysmenorrhoea Diseases 0.000 description 4
- 206010019233 Headaches Diseases 0.000 description 4
- 208000007502 anemia Diseases 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 230000000740 bleeding effect Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 208000002173 dizziness Diseases 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 231100000869 headache Toxicity 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000009245 menopause Effects 0.000 description 4
- 230000005906 menstruation Effects 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 208000008035 Back Pain Diseases 0.000 description 3
- 208000008930 Low Back Pain Diseases 0.000 description 3
- 208000017657 Menopausal disease Diseases 0.000 description 3
- 206010028813 Nausea Diseases 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- POZRVZJJTULAOH-LHZXLZLDSA-N danazol Chemical compound C1[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=CC2=C1C=NO2 POZRVZJJTULAOH-LHZXLZLDSA-N 0.000 description 3
- 229960000766 danazol Drugs 0.000 description 3
- 238000001647 drug administration Methods 0.000 description 3
- 229940121381 gonadotrophin releasing hormone (gnrh) antagonists Drugs 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000008693 nausea Effects 0.000 description 3
- 231100000957 no side effect Toxicity 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 229920001432 poly(L-lactide) Polymers 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 230000008719 thickening Effects 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 206010000084 Abdominal pain lower Diseases 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 206010010144 Completed suicide Diseases 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010053156 Musculoskeletal discomfort Diseases 0.000 description 2
- 206010067482 No adverse event Diseases 0.000 description 2
- 208000000450 Pelvic Pain Diseases 0.000 description 2
- 206010064229 Pelvic discomfort Diseases 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 208000021017 Weight Gain Diseases 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 2
- 239000001527 calcium lactate Substances 0.000 description 2
- 235000011086 calcium lactate Nutrition 0.000 description 2
- 229960002401 calcium lactate Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 230000000235 effect on cancer Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 230000002175 menstrual effect Effects 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 210000004303 peritoneum Anatomy 0.000 description 2
- 238000001050 pharmacotherapy Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000012744 reinforcing agent Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- 206010065687 Bone loss Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010006312 Breast swelling Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010016326 Feeling cold Diseases 0.000 description 1
- 206010060781 Haemorrhagic ovarian cyst Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000000857 Hepatic Insufficiency Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010036772 Proctalgia Diseases 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 206010046798 Uterine leiomyoma Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000001164 bioregulatory effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 150000002013 dioxins Chemical class 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 231100000507 endocrine disrupting Toxicity 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 201000009274 endometriosis of uterus Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000002474 gonadorelin antagonist Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 208000025661 ovarian cyst Diseases 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000003071 polychlorinated biphenyls Chemical class 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JPJP-P-2003-00109507 | 2003-04-14 | ||
| JP2003109507A JP2004175783A (ja) | 2003-04-14 | 2003-04-14 | 子宮内膜症及び婦人科疾患の治療薬 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20060002708A true KR20060002708A (ko) | 2006-01-09 |
Family
ID=32709287
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020047016387A Withdrawn KR20060002708A (ko) | 2003-04-14 | 2004-04-14 | 자궁내막증 및 부인과질환의 치료약 |
Country Status (3)
| Country | Link |
|---|---|
| JP (1) | JP2004175783A (enrdf_load_stackoverflow) |
| KR (1) | KR20060002708A (enrdf_load_stackoverflow) |
| WO (1) | WO2004091635A1 (enrdf_load_stackoverflow) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20190057999A (ko) | 2017-11-21 | 2019-05-29 | 경희대학교 산학협력단 | 데하이드로코스투스 락톤을 포함하는 자궁세포 이상증식 질환의 예방, 개선 또는 치료용 조성물 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3425968B2 (ja) * | 1992-05-15 | 2003-07-14 | 興研株式会社 | 人を含む動物の悪性腫瘍細胞増殖抑制剤 |
| JPH06336427A (ja) * | 1993-05-26 | 1994-12-06 | Global Art Kk | 人を含む動物の悪性腫瘍細胞増殖抑制剤 |
| JPH09227388A (ja) * | 1996-02-15 | 1997-09-02 | Naganushi Tetsuaki | 大腸癌、食道癌及び乳癌より選ばれた癌に用いる抗悪性腫瘍剤 |
| JPH10130153A (ja) * | 1996-10-28 | 1998-05-19 | Shiyumeidou:Kk | 大腸癌、食道癌及び乳癌より選ばれた癌に用いる 抗悪性腫瘍剤 |
| JP2001139476A (ja) * | 1999-11-15 | 2001-05-22 | Youichirou Naganushi | 癌を含めた悪性新生物に用いる抗悪性腫瘍剤 |
| AU2881301A (en) * | 2000-01-26 | 2001-08-07 | Amato Pharmaceutical Products, Ltd. | Cancer cell implantation inhibitors |
| US20040116520A1 (en) * | 2001-01-24 | 2004-06-17 | Amato Pharmaceutical Products, Ltd. | Anti-stress agents |
| JP2002356433A (ja) * | 2001-05-30 | 2002-12-13 | Tendou Seiyaku Kk | 免疫賦活剤 |
| US20040258657A1 (en) * | 2001-07-18 | 2004-12-23 | Mikio Watanabe | Antitumor agent containing cyclic polylactic acid |
| TW200300080A (en) * | 2001-11-06 | 2003-05-16 | Education Instr Co Ltd | Antitumor agent containing lactic acid oligomer mixture |
| JP2004155670A (ja) * | 2002-11-01 | 2004-06-03 | Youichirou Naganushi | 細胞賦活剤、細胞賦活剤製造方法及びその装置 |
-
2003
- 2003-04-14 JP JP2003109507A patent/JP2004175783A/ja active Pending
-
2004
- 2004-04-14 WO PCT/JP2004/005326 patent/WO2004091635A1/ja active Application Filing
- 2004-04-14 KR KR1020047016387A patent/KR20060002708A/ko not_active Withdrawn
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20190057999A (ko) | 2017-11-21 | 2019-05-29 | 경희대학교 산학협력단 | 데하이드로코스투스 락톤을 포함하는 자궁세포 이상증식 질환의 예방, 개선 또는 치료용 조성물 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2004175783A (ja) | 2004-06-24 |
| WO2004091635A1 (ja) | 2004-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hollander et al. | Antacids vs placebos in peptic ulcer therapy: a controlled double-blind investigation | |
| CA2554860A1 (en) | Pharmaceutical composition and method for the transdermal delivery of magnesium | |
| JP2002518456A (ja) | 脳血管の正常状態を支持するための栄養補助食品 | |
| EA021711B1 (ru) | Биологически активная добавка к пище для профилактики заболеваний остеопорозом | |
| Dieckmann et al. | Combined laser-steroid therapy in blue rubber bleb nevus syndrome: case report and review of the literature | |
| RU2346695C2 (ru) | Применение ксенона для коррекции патологических изменений в организме, связанных с нарушением антиоксидантного статуса | |
| US11596166B2 (en) | Compositions and methods for treating aging and/or improving human health | |
| KR20060002708A (ko) | 자궁내막증 및 부인과질환의 치료약 | |
| US7141251B2 (en) | Pharmacologically active strong acid solutions | |
| US20240374632A1 (en) | Apparatus and Method for Contact Free Delivery and Administration of Magnesium as a Drug | |
| ES2668943T3 (es) | Composición farmacéutica para tratar eyaculación precoz y método de tratamiento de la eyaculación precoz | |
| Kataria et al. | Trigeminal neuralgia induced headache: A case report and literature review | |
| JP3545512B2 (ja) | 生薬配合発泡錠 | |
| JPWO2002060457A1 (ja) | 抗ストレス剤 | |
| Furkatovna | Vitamin D Deficiency in Menopausa Women | |
| CN108992549A (zh) | 一种药物组合物及其制备方法、应用 | |
| Lemmer et al. | P-218: Normalisation of non-dipping blood pressure profile by amlodipine after single morning or evening dosing | |
| KR100584214B1 (ko) | 모려칼슘을 유효성분으로 하는 약효증진제의 제조방법 | |
| CN110101690B (zh) | 一种神经细胞保护剂及其在癫痫防治中的应用 | |
| RU2200550C2 (ru) | Новые лекарственные формы димоцифона в терапии лепры, зудящих и аллергодерматозов, герпетиформного дерматита дюринга | |
| Lurie et al. | Symptomatic hyponatremia following cesarean section | |
| Lewis | Breathless no more: Defeating adult sleep apnea. | |
| Warfield | The sympathetic dystrophies | |
| Aggoune | Clinical and therapeutic aspects of sickle cell disease in three clinical cases | |
| Morales-Borges | Flavonoids and ferrochel in women with iron deficiency anemia of abnormal uterine bleeding: our experience in community-based private hematology/oncology and integrative medicine practice |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20041013 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |